# A Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With Methotrexate Versus Methotrexate Alone in Patients With RA

> **NCT01709760** · PHASE3 · UNKNOWN · sponsor: **Mycenax Biotech Inc.** · enrollment: 91 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** ENIA11
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01709760
- **Lead sponsor:** Mycenax Biotech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-11
- **Primary completion:** 2017-12
- **Final completion:** 2019-12
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2018-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01709760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01709760, "A Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With Methotrexate Versus Methotrexate Alone in Patients With RA". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01709760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*